The goal of this observational study is to learn about the features of senescent T lymphocytes induced by chemotherapy and its relationship with the efficacy of neoadjuvant chemotherapy in young triple-negative breast cancer (TNBC) patients.
The main questions it aims to answer are:
* What are the senescent features of peripheral T lymphocytes in young TNBC patients receiving neoadjuvant chemotherapy and the relationship with the efficacy of neoadjuvant chemotherapy? * What is the relationship between senescent T cells and adverse events, DFS and tumor infiltrating lymphocytes?
1. Participants will receive 6 cycles of docetaxel + adriamycin/epirubicin + cyclophosphamide (TEC/TAC) neoadjuvant chemotherapy, and radical mastectomy after chemotherapy.
2.5ml peripheral venous blood will be collected before chemotherapy, after 2 cycles of chemotherapy, before surgery, and six months after surgery.
3.Clinicopathological data, chemotherapy-related adverse events and prognostic information of patients should be collected during the study.
Female, age≤40 years old,
Invasive breast cancer confirmed by pathology, immunohistochemistry showed TNBC (ER-, PR-, HER2-),
Indications for neoadjuvant chemotherapy according to guidelines: tumor diameter > 2cm or with axillary lymph node metastasis or desiring breast-conserving surgery but should obtain negative surgical margins through neoadjuvant chemotherapy.
Stage IV patients or a history of other malignancies,
Having microbial infection or autoimmune disease have not been cured or having HBV, HIV infection,
Having surgery 3 months before enrollment,
Patients with insufficient clinicopathological data,
young triple negative breast cancer patients receiving neoadjuvant chemotherapy
Cohort
Prospective
docetaxel, anthracycline, cyclophosphamide
Drug1. Participants were required to receive 6 cycles of TEC/TAC neoadjuvant chemotherapy, and radical mastectomy was required after chemotherapy. 2. 5ml peripheral venous blood was collected before chemotherapy, after 2 cycles of chemotherapy, before surgery, and six months after surgery. 3. Clinicopathological data, chemotherapy-related adverse events and prognostic information of patients should be collected during the study.
pCR
pathological complete response
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
